NeuroSci
August 27, 2025
Alexander Thomas, R Andrew Chambers
4 citations
Interest in ketamine as a novel treatment for substance use disorders (SUDs) has been increasing due to its N-methyl-D-aspartate (NMDA) glutamate receptor antagonism and mounting evidence that glutamate neurotransmission is involved in the pathogenesis of both depression and addictions. This narrative review provides an outline of clinical evidence reported in the literature from the 1970s to...
The FASEB Journal
August 26, 2025
Joshua C. Flowers, Paige E. Vetter, McKennon J. Wiles et al.
7 citations
ABSTRACT Chronic stress affects brain functions, leading to the development of mental disorders like anxiety and depression, as well as cognitive decline and social dysfunction. Among many biological changes in chronically stressed brains, disruptions in AMPA Receptor (AMPAR)‐mediated synaptic transmission in the hippocampus are associated with stress responses. We have revealed that low‐dose...
Scientific Reports
August 23, 2025
Kalin Manooki, Mahdieh Gholami, Maryam Eslami et al.
3 citations
Schizophrenia is a severe chronic neuropsychiatric disorder with a wide-range of cognitive and mental deficits and different categories of symptoms including positive, negative, and cognitive symptoms. In rodents, sub-chronic ketamine administration is a common method to induce a schizophrenia-like state. Olanzapine, an atypical antipsychotic medication, is used for the treatment and management...
The American Journal of Drug and Alcohol Abuse
August 22, 2025
P. Manza, Annabelle M. Belcher, Heather Fitzsimons et al.
ABSTRACT Background: Opioid use disorder (OUD) is a chronic relapsing condition with a high mortality rate. While medications such as methadone are valuable first-line therapies, retention is poor, with the highest dropout rates early in a treatment attempt. Poor outcomes are due in part to the very high rates of co-morbid depression in people with OUD, as depression can drive opioid use....
bioRxiv : the preprint server for biology
August 22, 2025
Jose A Cortes-Briones, Juan Urrutia-Gandolfo, Pablo A Estevez et al.
preprint
The balance between excitatory and inhibitory (E/I) activity is critical for brain function, and its disruption is implicated in neuropsychiatric disorders. Electrophysiological signals can be decomposed into periodic (oscillatory) and aperiodic components. In the power spectrum, the periodic component appears as narrowband peaks, while the aperiodic component underlies its characteristic 1 / f...
Annals of Indian Psychiatry
August 22, 2025
Swarndeep Singh, Saurabh Kumar, Shaily Mina et al.
Ketamine has emerged as a promising treatment strategy for several psychiatric disorders, with rising number of studies examining its safety and efficacy in Indian settings. However, concerns remain regarding their methodological robustness. To systematically review and evaluate the methodological quality of Indian studies assessing the use of ketamine for treating psychiatric disorders and...
Behavioural Pharmacology
August 21, 2025
Stephen W. White, Tara D. Clover, Kenneth J. Sufka
Pre- and probiotics promote a diverse and functional gut microbiota and have demonstrated both anxiolytic and antidepressant effects; however, how synbiotic diet interacts with antidepressant medications has not been fully investigated. This study sought to evaluate the potential anxiolytic or antidepressant effects of a synbiotic diet in an avian model that presents homologies with...
Frontiers in Nutrition
August 21, 2025
Jakub Słupski, Agnieszka Mechlińska, Adam Włodarczyk et al.
1 citation
Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BP), significantly impact global health, with MDD affecting over 300 million people and BP affecting approximately 2% of the world's population. Ketamine, originally an anesthetic, has emerged as a promising treatment for patients with treatment-resistant depression (TRD), due to its unique pharmacological...
Psychiatry Research
August 20, 2025
L. Mcinnes, Robert M. Berman, Matthew J Worley et al.
OBJECTIVE The study evaluated the effectiveness of Ketamine Intravenous Therapy (KIT) in reducing post-traumatic stress disorder (PTSD) and depression symptoms, using electronic health record data from outpatient psychiatric patients with PTSD. METHOD We analyzed data from 8,136 patients diagnosed with PTSD, 87 % (N = 7,070) of whom also had comorbid depression. Symptom severity was measured...
The International Journal of Neuropsychopharmacology
August 18, 2025
B Baune, E Van Assche
Abstract Background DNA methylation is a biomarker suited to investigate dynamic processes, such as treatment response. For this analysis we focus on DNA methylation changes during a randomised controlled trial (RCT) in treatment resistant depressed patients comparing racemic ketamine (s.c.) versus midazolam (s.c.) (the Ketamine for Adult Depression Study - KADS). This clinical trial showed a...